TY - JOUR
T1 - Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients
AU - Belzil, Veronique V.
AU - Bauer, Peter O.
AU - Gendron, Tania F.
AU - Murray, Melissa E.
AU - Dickson, Dennis
AU - Petrucelli, Leonard
N1 - Funding Information:
We would like to thank the patients involved in this study as well as acknowledge the technical support of Caroline T. Stetler, Mercedes Prudencio, Amanda M. Liesinger, and Linda G. Rousseau from Mayo Clinic, as well as Brent DiGiorgio from Softgenetics. This work was supported by Mayo Clinic Foundation (LP), National Institutes of Health/National Institute on Aging [ R01AG026251 (LP)], National Institutes of Health/National Institute of Neurological Disorders and Stroke [ R01 NS 063964-01 (LP), R01 NS077402 (LP), and ES20395-01 (LP)], Amyotrophic Lateral Sclerosis Association (LP, POB), the Canadian Institutes of Health Research (VVB), and the Siragusa Foundation (VVB).
Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2014/10/10
Y1 - 2014/10/10
N2 - A significant number of patients suffering from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two diseases commonly seen in comorbidity, carry an expanded noncoding hexanucleotide repeat in the C9orf72 gene, a condition collectively referred to as c9FTD/ALS. Repeat expansions, also present in other neurodegenerative diseases, have been shown to alter epigenetic mechanisms and consequently lead to decreased gene expression, while also leading to toxic RNA gain-of-function. As expression of multiple C9orf72 transcript variants is known to be reduced in c9FTD/ALS cases, our group and others have sought to uncover the mechanisms causing this reduction. We recently demonstrated that histones H3 and H4 undergo trimethylation at lysines 9 (H3K9), 27 (H3K27), 79 (H3K79), and 20 (H4K20) in all pathogenic repeat carrier brain samples, confirming the role of altered histone methylation in disease. It was also reported that about 40% of c9ALS cases show hypermethylation of the CpG island located at the 5' end of the repeat expansion in blood, frontal cortex, and spinal cord. To determine whether the same CpG island is hypermethylated in the cerebella of cases in whom aberrant histone methylation has been identified, we bisulfite-modified the extracted DNA and PCR-amplified 26 CpG sites within the C9orf72 promoter region. Among the ten c9FTD/ALS (4 c9ALS, 6 c9FTD), nine FTD/ALS, and eight disease control samples evaluated, only one c9FTD sample was found to be hypermethylated within the C9orf72 promoter region. This study is the first to report cerebellar hypermethylation in c9FTD/ALS, and the first to identify a c9FTD patient with aberrant DNA methylation. Future studies will need to evaluate hypermethylation of the C9orf72 promoter in a larger cohort of c9FTD patients, and to assess whether DNA methylation variation across brain regions reflects disease phenotype. This article is part of a Special Issue entitled RNA Metabolism 2013.
AB - A significant number of patients suffering from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two diseases commonly seen in comorbidity, carry an expanded noncoding hexanucleotide repeat in the C9orf72 gene, a condition collectively referred to as c9FTD/ALS. Repeat expansions, also present in other neurodegenerative diseases, have been shown to alter epigenetic mechanisms and consequently lead to decreased gene expression, while also leading to toxic RNA gain-of-function. As expression of multiple C9orf72 transcript variants is known to be reduced in c9FTD/ALS cases, our group and others have sought to uncover the mechanisms causing this reduction. We recently demonstrated that histones H3 and H4 undergo trimethylation at lysines 9 (H3K9), 27 (H3K27), 79 (H3K79), and 20 (H4K20) in all pathogenic repeat carrier brain samples, confirming the role of altered histone methylation in disease. It was also reported that about 40% of c9ALS cases show hypermethylation of the CpG island located at the 5' end of the repeat expansion in blood, frontal cortex, and spinal cord. To determine whether the same CpG island is hypermethylated in the cerebella of cases in whom aberrant histone methylation has been identified, we bisulfite-modified the extracted DNA and PCR-amplified 26 CpG sites within the C9orf72 promoter region. Among the ten c9FTD/ALS (4 c9ALS, 6 c9FTD), nine FTD/ALS, and eight disease control samples evaluated, only one c9FTD sample was found to be hypermethylated within the C9orf72 promoter region. This study is the first to report cerebellar hypermethylation in c9FTD/ALS, and the first to identify a c9FTD patient with aberrant DNA methylation. Future studies will need to evaluate hypermethylation of the C9orf72 promoter in a larger cohort of c9FTD patients, and to assess whether DNA methylation variation across brain regions reflects disease phenotype. This article is part of a Special Issue entitled RNA Metabolism 2013.
KW - Amyotrophic lateral sclerosis
KW - C9orf72
KW - DNA methylation
KW - Epigenetics
KW - Frontotemporal dementia
KW - Repeat expansion
UR - http://www.scopus.com/inward/record.url?scp=84907681995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907681995&partnerID=8YFLogxK
U2 - 10.1016/j.brainres.2014.02.015
DO - 10.1016/j.brainres.2014.02.015
M3 - Article
C2 - 24530272
AN - SCOPUS:84907681995
SN - 0006-8993
VL - 1584
SP - 15
EP - 21
JO - Brain Research
JF - Brain Research
ER -